Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 3

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 3
---
205) 
     424,091 

    Net Loss – Noncontrolling Interest 
     (752) 
     (2,485)
  
    Comprehensive (Loss) Income – attributed to 60 Degrees Pharmaceuticals, Inc. 
     (1,886,453) 
     426,576 

    Cumulative Dividends on Series A Preferred Stock 
     (118,158) 
     (117,881)
  
    Net (Loss) Income - attributed to common stockholders 
    $(2,004,611) 
    $308,695 

    Net (Loss) Income per Common Share: 

    Basic and Diluted 
    $(1.56) 
    $1.83 
  
    Weighted Average Number of Common Shares Outstanding(1) 

    Basic and Diluted 
     1,283,462  
     168,756 

(1)Prior periods presented have been adjusted to reflect the
1:12 reverse stock split on August 12, 2024 and the 1:5 reverse stock split on February 24, 2025.

The accompanying notes are an integral part
of these unaudited consolidated condensed financial statements.

2

60 DEGREES PHARMACEUTICALS, INC.

CONSOLIDATED CONDENSED STATEMENTS OF SHAREHOLDERS’
EQUITY (UNAUDITED)

    For the Three Months Ended March 31, 2025 

     Series A Preferred Stock  
    Common Stock(1)  
    Additional Paid-In  
    Accumulated  
    Accumulated 
Other
 Comprehensive  
    Total Shareholders’
    Equity Attributable  
    Noncontrolling  Interest on  
    Total  Shareholders’ 

    Shares  
    Amount  
    Shares  
    Amount  
     Capital(1)  
     Deficit  
    Income (Loss)  
     to 60P  
     Shareholders  
    Equity 
  
    Balance—December 31, 2024 
     76,480  
    $9,567,439  
     566,908  
    $57  
    $34,860,590  
    $(40,527,957) 
    $135,471  
    $4,035,600  
    $(80,594) 
    $3,955,